Actualités Faron Pharmaceuticals Oy - FARN | Actions London Stock Exchange

Faron announces promising findings from blood cancer drug trial

Faron Pharmaceuticals Ltd on Wednesday reported positive data from an ongoing trial on patients receiving a new treat ...

Faron Pharmaceuticals Oy Positive Phase 2 Interim Results from BEXMAB Trial

Faron Pharmaceuticals Oy 27 November 2024 Faron Pharmaceuticals Ltd. ("Faron" or "the Company") Inside Information: Faron Announces...

Faron Pharmaceuticals Oy Shareholders’ Nomination Board

Faron Pharmaceuticals Oy 05 November 2024 ("Faron" or "the Company") Composition of Faron Pharmaceutical's Shareholders' Nomination Board ...

Faron Pharmaceuticals Oy Faron’s Capital Markets Day 2024

Faron Pharmaceuticals Oy 22 October 2024 Faron Pharmaceuticals Ltd. ("Faron" or "the Company") Faron's Capital Markets Day 2024 - BEXMAB...

Faron Pharmaceuticals Oy Grant of options

Faron Pharmaceuticals Oy 30 August 2024 Faron Pharmaceuticals Ltd. ("Faron" or "the Company") Grant of options Company announcement...

Faron Pharma shares surge as US FDA grants fast track designation

Faron Pharmaceuticals Ltd on Tuesday said its loss widened in the first half of 2024, as the company successfully adv ...

Faron Pharmaceuticals Oy FDA Grants Fast Track Designation for Bexmarilimab

Faron Pharmaceuticals Oy 26 August 2024 Faron Pharmaceuticals Ltd. ("Faron" or the "Company") Inside Information: FDA Grants Fast Track...

Faron Pharmaceuticals Oy Faron 2024 Half-Year Financial Results

Faron Pharmaceuticals Oy 27 August 2024 Faron Pharmaceuticals Ltd. ("Faron" or "the Company") Faron Reports Half-Year Financial Results, 1...

Faron Pharmaceuticals Oy Notice of Half-Year Financial Results

Faron Pharmaceuticals Oy 20 August 2024 Faron Pharmaceuticals Ltd. ("Faron" or the "Company") Faron Pharmaceuticals Notice of Half-Year...

IN BRIEF: Faron Pharmaceuticals joins US grant for battlefield wounds

cals Ltd - Turku, Finland-based clinical-stage biopharmaceutical maker - Joins consortium that has received a USD1.5 m ...

EXECUTIVE CHANGES: New chief executives at Cornish Metals and ValiRx

The following is a round-up of London-listed company director and manager changes announced in August so far and not ...

Faron Pharmaceuticals Oy Appointment of Chief Financial Officer

Faron Pharmaceuticals Oy 08 August 2024 Faron Pharmaceuticals Ltd. ("Faron" or the "Company") Appointment of Chief Financial Officer ...

Faron Pharmaceuticals Oy Grant of options

Faron Pharmaceuticals Oy 07 August 2024 Faron Pharmaceuticals Ltd. ("Faron" or "the Company") Grant of options Company announcement...

IN BRIEF: Faron Pharmaceuticals names Petri Bono as CMO

cals Oy - Turku, Finland-based clinical-stage biopharmaceutical company - Names Petri Bono as the new chief medical of ...

Faron Pharmaceuticals Oy Faron Appoints Dr. Petri Bono as new CMO

Faron Pharmaceuticals Oy 06 August 2024 Faron Pharmaceuticals Ltd. ("Faron" or the "Company") Faron Appoints Dr. Petri Bono as new CMO ...

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Faron Pharmaceuticals Oy (FARN)

Outils de qualité professionnelle, pour des investisseurs individuels.

FARN Actualités

Faron announces promising findings from blood cancer drug trial

Faron Pharmaceuticals Oy Positive Phase 2 Interim Results from BEXMAB Trial

Faron Pharmaceuticals Oy Shareholders’ Nomination Board

Faron Pharmaceuticals Oy Faron’s Capital Markets Day 2024

Faron Pharmaceuticals Oy Grant of options

Faron Pharma shares surge as US FDA grants fast track designation

Faron Pharmaceuticals Oy FDA Grants Fast Track Designation for Bexmarilimab

Faron Pharmaceuticals Oy Faron 2024 Half-Year Financial Results

Faron Pharmaceuticals Oy Notice of Half-Year Financial Results

IN BRIEF: Faron Pharmaceuticals joins US grant for battlefield wounds

EXECUTIVE CHANGES: New chief executives at Cornish Metals and ValiRx

Faron Pharmaceuticals Oy Appointment of Chief Financial Officer

Faron Pharmaceuticals Oy Grant of options

IN BRIEF: Faron Pharmaceuticals names Petri Bono as CMO

Faron Pharmaceuticals Oy Faron Appoints Dr. Petri Bono as new CMO

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

BLACK FRIDAY

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Faron Pharmaceuticals Oy (FARN) Actualités

Faron Pharmaceuticals Oy (FARN)

Outils de qualité professionnelle, pour des investisseurs individuels.

FARN Actualités

Faron announces promising findings from blood cancer drug trial

Faron Pharmaceuticals Oy Positive Phase 2 Interim Results from BEXMAB Trial

Faron Pharmaceuticals Oy Shareholders’ Nomination Board

Faron Pharmaceuticals Oy Faron’s Capital Markets Day 2024

Faron Pharmaceuticals Oy Grant of options

Faron Pharma shares surge as US FDA grants fast track designation

Faron Pharmaceuticals Oy FDA Grants Fast Track Designation for Bexmarilimab

Faron Pharmaceuticals Oy Faron 2024 Half-Year Financial Results

Faron Pharmaceuticals Oy Notice of Half-Year Financial Results

IN BRIEF: Faron Pharmaceuticals joins US grant for battlefield wounds

EXECUTIVE CHANGES: New chief executives at Cornish Metals and ValiRx

Faron Pharmaceuticals Oy Appointment of Chief Financial Officer

Faron Pharmaceuticals Oy Grant of options

IN BRIEF: Faron Pharmaceuticals names Petri Bono as CMO

Faron Pharmaceuticals Oy Faron Appoints Dr. Petri Bono as new CMO

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

BLACK FRIDAY

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres